A Study of Telitacicept for IgA Nephropathy (TELIGAN)

Summary

The purpose of this study is to evaluate the efficacy and safety of Telitacicept in patients with primary IgA nephropathy at risk of progressing to end-stage renal disease(ESRD), despite maximum tolerated treatment with renin-angiotensin system(RAS) blockade using angiotensin converting enzyme inhibitors (ACEIs) or angiotensin II type I receptor blockers (ARBs).

Timeline

Start

2023-04-28

Primary completion

2026-06

Completion

2026-06

Publications

• Lv J, Liu L, Wang W, Wang X, Zuraw Q, Perkovic V, Fang J, Zhang H; TELIGAN Investigators. Telitacicept for IgA Nephropathy - Interim Analysis of a Phase 3 Trial. N Engl J Med. 2026 May 14;394(19):1916-1924. doi: 10.1056/NEJMoa2514415.
• Tunnicliffe DJ, Reid S, Craig JC, Samuels JA, Molony DA, Strippoli GF. Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev. 2024 Feb 1;2(2):CD003962. doi: 10.1002/14651858.CD003962.pub3.

Drugs

Indications